Xu Mengjiao, Zhang Zhiyu, Zhang Zhoudong, Liu Dong, Shang Yanguo, Tang Chenglun, Wang Weipeng, Li Huanqiu, You Bengang, Ying Hanjie, Shen Tao
College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China.
College of Pharmaceutical Sciences, Soochow University, Suzhou 215006, China.
Neurol Int. 2025 Aug 4;17(8):120. doi: 10.3390/neurolint17080120.
Depression is a common mental disorder with high economic burden, characterized by high disability and mortality rates. The etiology of depression remains unclear to date, and there are various hypotheses regarding the pathogenesis of depression in clinical practice, including the monoamine neurotransmitter hypothesis, the hypothalamic-pituitary-adrenal (HPA) axis dysregulation hypothesis, the inflammatory cytokine hypothesis, and the neurotrophic factor hypothesis. These theories offer specific directional aid in the clinical management of individuals suffering from depression. Medicinal intervention stands as a critical approach within the spectrum of depression treatments, and this article reviews the specific mechanisms of different hypotheses on the pathogenesis of depression in recent years, as well as the research progress on related therapeutic drugs.
抑郁症是一种常见的精神障碍，经济负担沉重，其特点是致残率和死亡率高。抑郁症的病因至今仍不清楚，临床实践中有多种关于抑郁症发病机制的假说，包括单胺神经递质假说、下丘脑 - 垂体 - 肾上腺（HPA）轴失调假说、炎性细胞因子假说和神经营养因子假说。这些理论为抑郁症患者的临床管理提供了特定的指导方向。药物干预是抑郁症治疗范围内的一种关键方法，本文综述了近年来不同抑郁症发病机制假说的具体机制以及相关治疗药物的研究进展。
